Opinion statement
No child psychiatric disorder has a single treatment that is completely satisfactory. Combinations are sometimes more beneficial than single treatments. This is well established for medication+behavioral treatment for depression and ADHD. There is wide variability in the evidence base for various treatments, from FDA-approved RCTs to open pilots. In the search for additional or alternative treatments, essential fatty acids seem especially to pass the SECS criterion: a treatment that is safe, easy, cheap, and sensible does not need as much evidence to justify patient trials as one that is risky, unrealistic, difficult, or expensive (RUDE). Not only do omega-3 fatty acids have some RCT evidence for a small effect in several psychiatric disorders, but they also are believed useful in preventing cardiac morbidity and excessive inflammation. Therefore, for ADHD, we recommend a combination of behavioral treatment (e.g., parent training, cognitive-behavioral therapy (CBT) for older patients), FDA-approved medication, (primarily stimulants), an RDI/RDA multivitamin/mineral to compensate for stimulant appetite suppression, and about a gram a day of EPA/DHA, possibly supplemented with 50-100 mg GLA. For mood disorders, we recommend a combination of mood stabilizer or antidepressant (depending on which mood disorder), CBT, RDA/RDI multivitamin/mineral (in view of reported vitamin D deficiencies and vitamin wasting from some anticonvulsant mood stabilizers), and a gram per day of EPA/DHA. For autism, we recommend applied behavior analysis, RDA/RDI multivitamin/mineral in view of the often idiosyncratic unbalanced diet, ADHD medication if a problem with hyperactivity, antipsychotic if a problem with irritability/aggression, and omega-3 for anti-inflammatory effect. For learning disorder and developmental coordination disorder, we recommend remedial tutoring or occupational therapy and EPA/DHA. For children at high risk for psychosis or mood disorder, we recommend counseling, monitoring for early indication of low-dose antipsychotic, and general nutritional support, including EPA/DHA. For Tourette's and aggression, EPA/DHA and other nutritional support can be added to standard treatment. When using fish oil, it is important to make sure it was refined to eliminate contaminants such as mercury. The effect accumulates gradually over months. There is no convincing evidence of greater benefit but some risk from amounts over a gram or two per day.
Introduction
Brief history of childhood psychiatric illnesses As many as 20 % of the world's children may be affected by a psychiatric or neurodevelopmental disorder [1] . Their families may seek complementary and alternative (CAM) treatments as psychotropic providers and treatments may not be available; financial resources, cultural acceptance, or concern about potential adverse side effects or developmental consequences of conventional established treatment also influence desire to use a CAM modality.
Overview of current treatment options
For the disorders reviewed here, the conventional psychopharmacologic treatments (psychostimulants, antidepressants, antipsychotics, and classic mood stabilizers) are limited by response rates and tolerability, which are both unpredictable. Tolerability concerns include the following: appetite and weight changes; sedation and dizziness; bleeding, blood pressure, and heart rate changes [2] ; alterations in sleep; and undesired changes in mood, or worsening of or emergence of suicidal ideation. Adverse effects can be subclinical when viewed at individual visits but over time may build to serious clinical sequelae such as type 2 diabetes, cardiovascular disease, or neurological impairment. Thus, effective and better tolerated options are critical to improving o u t c o m e s o f c h i l d h o o d p s y c h i a t r i c a n d neurodevelopmental disorders. CAM may also offer population health strategies for preventing these disorders.
Of the many potential CAM treatments being examined for prevention and intervention in child and adolescent disorders, omega-3 polyunsaturated fatty acid (PUFA) supplementation is one of the most promising, with supportive data for basic and clinical mechanism of action and epidemiologic studies. Randomized controlled trials (RCTs) are building evidence of benefit for several disorders, as well as for maximizing developmental potential and preventing brain-based disorders as well as associated metabolic health sequelae [3, 4, 5•] .
Roles and possible mechanisms of omega-3 PUFAs Essential fatty acids (omega-3 and omega-6 PUFAs) are obtained only through diet. Omega-3 PUFAs, chiefly docosahexaenoic acid (DHA), are necessary during pregnancy, infancy, and early childhood for appropriate development and function of the central nervous system. With adequate dietary intake, over 20 % of brain lipid is DHA, and combined with another fraction as eicosapentaenoic acid (EPA), both contribute to neuronal cell membrane structure, fluidity, and receptor function. The decline of dietary ratios of omega-3:omega-6 PUFAs across the last century have very possibly contributed to greater rates of psychiatric illness and symptom expression [6••].
Omega-3 PUFAs are linked to dopaminergic function in adults with major depressive disorder [7] . They also help regulate inflammation. Eicosanoids, signaling molecules derived from omega-3 and omega-6 PUFAs, include prostaglandins and leukotrienes. Series 2 eicosanoids, from omega-6 (arachidonic acid, AA), are proinflammatory, and series 1 and 3 (from omega-6 (dihomogammalineolenic acid, GLA) and from omega-3 (eicosapentaenoic acid, EPA) are mainly anti-inflammatory. Inflammation plays a role in many pathophysiological conditions [8] including the psychiatric and neurodevelopmental disorders listed below, providing potential mechanisms for study. The studies listed below include primarily omega-3 FA RCTs.
Summary of cost-effectiveness
There are not yet sufficient reports to determine costeffectiveness of treatment or prevention effects to make a definitive statement for childhood mental disorders, although the role of fish oils in population health (such as improved IQ) may be compelling for promotion of brain development during pregnancy [9•] . N-3 FA supplementation was safe and welltolerated in the trials reported below, without association to any serious adverse events to date or significant difference in tolerability from placebo, outside of the fish oil taste and odor when not masked. The most frequently reported adverse events have included difficulty swallowing large capsules, nausea, dyspepsia, vomiting, diarrhea, abdominal pain, and headaches, which were transient, self-limited, and equally reported in the groups taking placebo. Though no clinical trial has provided evidence for safety issues, there is a risk of contamination (mercury, other chemicals) in fish oil that is not purified.
Baseline and post-treatment serum markers from some omega-3 FA studies included plasma or RBC fatty acid concentrations, which can determine the extent to which subjects absorbed the oil (a potential compliance marker), or evidence of whether subjects converted alpha-linoleic acid (ALA) to bioavailable EPA/DHA.
The evidence justifying use is overall not conclusive for all children. A recurring theme through findings from treating children with omega-3 FAs is that certain children, depending on their n-3 FA dietary intake and other factors, such as genetic ability to convert DHA to EPA, may benefit more than others. In part related to limited efficacy of current pharmacologic treatments, their possibility of serious side effects, and the cost of adjunct omega-3 FA therapy as generally similar to or less than a monthly copay for conventional psychopharmacology, the American Psychiatric Association Task Force on Complementary and Alternative Medicine has recommended that for patients with poor impulse control, mood disorders, or psychotic disorders, the dietary intake of EPA+DHA should approximate 1 gram per day.
Omega-3 fatty acid treatments in children ADD/ADHD
& N-3 supplementation to treat hyperactivity and inattention symptoms has a Grade C evidence base, according to standards established by the U.S. Preventive Services Task Force (USPSTF). There is moderate certainty of small benefit, based on at least 19 RCTs, one other trial, and four meta-analyses in a total of 1884 children.
& Of the 14 studies that measured biomarkers of n-3 FA composition, most found elevated cheek cell, serum, or RBC n-3 FA levels after treatment, at least marginally over control groups, which correlated with clinical improvement [12-19, 29-31, 34] . With the exception of one study [24] , children with lower n-3/n-6 ratios at baseline exhibited better clinical response than the overall treated sample [13, 14, 19] .
& Thirteen studies (using 11 datasets) reported significant improvement in inattention, cognition, or hyperactivity via a primary [10-12, 15, 16, 19, 25-28, 30, 33] or secondary measure [20] . However, evidence was limited by confounded and inconsistent treatment formulations that may have included EPA, DHA, LA, ALA, GLA, methylphenidate, phosphatidylserine, and micronutrients. The more responsive children included those with the following: comorbid learning difficulties [13, 14] , comorbid neurodevelopmental disorders (motor control and perception) [17, 18] , inattentive type ADHD [17, 18] , oppositional symptoms [19] , and more pronounced hyperactivity and impulsivity symptoms [20] .
& N-3 FAs were better tolerated and only slightly less effective than methylphenidate [21, 25, 26] . Though the combination of methylphenidate and n-3 FAs offered no additional benefit over methylphenidate monotherapy, the combination allowed for slightly lower methylphenidate doses [25] . & Findings do not support the use of ALA or LA supplementation alone [22] [23] [24] 
Tourette's disorder
& There is insufficient evidence to determine efficacy of n-3 FAs for treating tics for children with Tourette's Disorder. In the single pertinent published RCT to date, n-3 FA supplementation did not reduce tic severity (number, intensity, frequency, complexity, and interference); however, it did reduce overall tic-related impairment on self-esteem, school, family, and social functioning [35] . 
Clinical evidence

Dyspraxia/developmental coordination disorder
& There is insufficient evidence to determine efficacy of n-3 FAs for treating motor impairment that is not due to a generalized medical condition (e.g. cerebral palsy). To date, one small trial reports improved motor function after DHA and AA supplementation, a positive finding that awaits confirmation. The single published RCT of children with developmental coordination disorder (DCD) reported a treatment effect, not on motor impairment, but on reading, spelling, and ADHD-related behavioral symptoms [36] , consistent with other studies done with samples with dyslexia [38] and ADHD [18] .
Clinical evidence Dyslexia and cognitive functioning
& There is insufficient evidence to determine treatment efficacy of n-3 FAs for treating dyslexia, reading problems, and other learning disabilities. The RCT focused on children with dyslexia provides no evidence of reading improvement [40] . Two of the three RCTs evaluating healthy children [38, 39, 41] found mild benefit in reading fluency [38] and listening comprehension [39] . 
Clinical evidence
Autism spectrum disorders
& There is insufficient evidence to determine efficacy of n-3 FAs on autism. To date, results of five RCTs have been published with children with autism and provide no evidence of reduction in behavioral and developmental outcomes. However, most of the studies were underpowered.
Clinical evidence Psychosis and personality disorders
& There is insufficient evidence to determine efficacy of n-3 FAs on psychosis. To date, one RCT [49••] has been published examining clinical symptoms of adolescents and young adults with subthreshold psychosis and borderline personality disorders. It, along with a posthoc analysis [50] and enzymatic study [51] , provides suggestive but insufficient evidence. Large, well-designed randomized controlled trials are required to determine the clinical efficacy of n-3 FA supplementation for youth at risk for developing their first psychotic episode. 
Clinical evidence
Aggression & To date, two published RCTs have assessed efficacy in reducing aggression among both healthy schoolchildren [52] and those and with disruptive behavior disorders [53] . These provide suggestive but insufficient evidence. Additional large, well-designed randomized controlled trials are required.
Clinical evidence Bipolar disorder
& There is insufficient evidence to determine efficacy. Of the three studies published with children with bipolar disorder, the only RCT [54] used alpha-linoleic acid (ALA); patients taking the ALA supplement were significantly more compliant but did not exhibit a significant conversion rate of ALA to EPA. Only the subgroup of subjects who acquired an EPA serum level of 0.8 % or higher exhibited a clinical response to the treatment. Since conversion from ALA to EPA was limited and required a minimum of 10-12 capsules/day, the authors concluded that an ALA treatment regimen is impractical.
The two prospective open-label trials [55, 56] provide suggestive, non-significant evidence of reduction and remission of symptoms. Clinical evidence Discussion/conclusion
Clinical evidence
Omega-3 fatty acids have been explored for a wide-ranging variety of child/ adolescent disorders. In general, effects have been small, but in several disorders significant. The small benefit is balanced by an even smaller safety risk as long as only mercuryfree oils are used in moderate doses (not more than 2-3 g/day), and intake of antioxidant vitamins is adequate. Theoretically alpha-linolenic acid (ALA), the 18-carbon precursor, should be elongated and further desaturated to make the 20-carbon eicosapentaenoic (EPA and 22-carbon docosahexaenoic (DHA)) acids that are critical to brain health and function. However, one of the genetic predispositions to mental disorders may be a deficient fatty acid desaturase enzyme necessary for the anabolism of EPA and DHA from ALA. Indeed, what few data are available suggest that ALA does not work as well as EPA/DHA. At least one meta-analysis suggested that EPA is the most important of all to ingest. This is the precursor not only of DHA, but also of anti-inflammatory prostaglandins and other "eicosanoids." All things considered, including general health, we recommend modest doses of EPA/DHA (up to a gram per day) if the child does not eat oily wild ocean fish three times a week. This should be coupled with adequate intake of vitamins and minerals. Higher doses may be tried for disorders that have some evidence of efficacy. Three months are needed for an adequate trial.
This review summarizes historical importance of omega-3 fatty acids in neurodevelopment, describing brain composition (including neuronal membrane properties), CNS accrual, and effects of deficit states in animals and humans on neuronal functioning, cellular signaling, and outcomes, including risk for psychopathology including ADHD and schizophrenia. 
